Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients after Mitral Valve Replacement

Shubin Li (✉ 349251538@qq.com )
Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital

Yang Gao
Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital

Mingqiu Hu
Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital

Yuehuan Li
Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital

Xu Meng
Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital

Research Article

Keywords: SAMe-TT2R2 score, anticoagulation control, time in therapeutic range, mitral valve replacement

DOI: https://doi.org/10.21203/rs.3.rs-290512/v1

License: ☇️ 📧 This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background:

This study aimed to evaluate the role of SAMe-TT$_2$R$_2$ score in the prediction of anticoagulation control after mechanical mitral valve replacement.

Methods and Results:

We retrospectively reviewed clinical data of 161 patients who received mechanical mitral valve replacement at Beijing Anzhen Hospital from January 2013 to December 2013. Collected data included general information of patients, medication and smoking, postoperative embolism due to anticoagulant, bleeding complications and death information.

In the SAMe-TT$_2$R$_2$ score results, the lowest score was 2 points (6.3%), the highest score was 7 points (0.7%). The number of people with 4 points was the largest, 60 people (41.4%). When the cut-off value of SAMe-TT$_2$R$_2$ score was set to $\geq 4$, the sensitivity and specificity of predicting TTR $\geq 65\%$ were 69.8% and 93.1%, respectively. The Youden index was 0.629. If the cut-off value of SAMe-TT$_2$R$_2$ score was set to $\leq 4$, the sensitivity and specificity of predicting TTR $\geq 65\%$ were 93.0% and 44.1%, respectively, and the Youden index was 0.371.

ROC curve evaluates the predictive power of the SAMe-TT$_2$R$_2$ score for TTR $\geq 65\%$. The figure showed that when the cut-off point $\geq 4$, the best combination of sensitivity and specificity was shown (69.8% and 93.1%, respectively). The area under the curve AUC was 0.854.

Conclusions:

After mechanical mitral valve replacement, the SAME-TT$_2$R$_2$ model can effectively predict the level of TTR during the course of using oral warfarin anticoagulation, and the SAMe-TT$_2$R$_2$ score $\geq 4$ can be used to predict TTR $< 65\%$.

Introduction

Thrombotic complications are prone to occur after mechanical mitral valve replacement, and patients need long-term oral warfarin anticoagulation therapy. [1] The complications such as thromboembolism and bleeding caused by improper anticoagulation seriously affect the patient's long-term life quality and prognosis after the surgery. [2] TTR is an important indicator of the level of anticoagulation quality. A high score of TTR indicates that the patient's anticoagulation situation is good and the probability of anticoagulation-related complications is low. [3] This study found that SAMe-TT$_2$R$_2$ score can effectively predict the level of TTR, which provides a reference for further improving the quality of postoperative anticoagulation.
Materials And Method

This was an observational retrospective cohort study conducted among 168 patients who underwent mechanical mitral valve replacement at Beijing Anzhen Hospital from January 2013 to December 2013. Five person lost to follow-up due to address and mobile phone number changes, and two refused the operation after review and follow-up, 161 cases were included in this study, and the loss to follow-up rate was 4.2%.

All the patients had no previous history of bleeding disorders, and they can insist on taking warfarin for anticoagulation therapy after the operation. Patients were excluded who can’t adhere to the warfarin treatment after the surgery. We also excluded the patients with severe liver and kidney dysfunction, hyperthyroidism, performed coronary artery bypass grafting and aortic valve replacement during the operation and patients who were pregnant as well as patients unable to complete the follow-up.

Collected data included general information of patients, medication and smoking, postoperative embolism due to anticoagulant, bleeding complications and death information. We collected the information through telephone follow-up, outpatient review, WeChat, and in combination with the database information of the Beijing Anzhen Hospital. The INR (international normalized ratio) values of the patients during the follow-up period were recorded, In the meantime the INR cycle were monitored. The European Society of Cardiology (ESC) and the European Society of Cardiothoracic Surgery (EACTS) in 2017 released the guidelines for the management of valvular heart disease and recommended a target value of 3.0 for the INR.\(^4\) But the differences between races and regions have caused large differences in anticoagulant strength from abroad. In Asia, low-dose anticoagulation is the highly recommended.\(^5\)[6][7][8] Based on the previous research and practice in our heart center, we determined the target value of INR to be 1.8–2.2.

TTR calculation: TTR (time in therapeutic range, TTR) is a way to evaluate the quality of anticoagulation control. A higher TTR score can effectively reduce warfarin-related bleeding and thrombosis events. Rosendaal method was used to calculate TTR, that is to say, the time redistribution between INR of two adjacent tests was used to calculate it.\(^9\) The anticoagulation quality is satisfactory when TTR score \(\geq 65\%)^{10}[11].

SAMe-TT\(_2\)R\(_2\) Score Definition: \(S:\) gender, 1 point for female; \(A:\) age, 1 point for < 60 years old; \(M:\) medical history, 1 point for people with more than 2 comorbid diseases, including hypertension, diabetes, coronary artery disease Myocardial infarction, peripheral artery disease, congestive heart failure, history of stroke, lung disease, liver or kidney disease; \(T:\) treatment, 1 point, such as amiodarone for rhythm control; \(R:\) smoking (within 2 years), 2 Points; \(R:\) race, 2 points for non-white.\(^{12}\) Since all patients in our study are Chinese, the minimum score is 2 points.

Statistical Analysis
Measurement data expressed as mean ± standard deviation (x±s), performed by normality test. Comparison of categorical data adopted the chi-square test. All tests were two-sided, and p-values were considered significant if < 0.05. Calculations were performed using SPSS software (version 22.0). The receiver operator characteristic curve (ROC) curve was used to determine the best node and predict the performance of sub-optimal TTR. Kaplan-Meier survival curve was used to analyze the death of patients with different SAMe-TT$_2$R$_2$ scores.

**Results**

161 patients successfully completed the follow-up research (54 males, 106 females, mean age 53.4 ± 8.4 years) and the median follow-up time were 1749 (1631, 2004) days. In the SAMe-TT$_2$R$_2$ score results, the lowest score was 2 points (6.3%), the highest score was 7 points (0.7%). The number of people with 4 points was the largest, 60 people (41.4%). The demographic characteristics of the sample are shown in Table 1.

During the follow-up period, a total of 4087 INR examinations were performed, and the median number of INR was 2.07. The INR results between 1.8–2.2 were 2207 times, accounting for 54.0%, the INR exceeding 2.2 were 1102 times (27.0%), and the INR less than 1.8 were 778 times (19.0%). The median TTR was 43.8% (31.7%, 65.6%).

Among the various indicators for evaluating the SAMe-TT$_2$R$_2$ score, apart from ethnic factors, gender factors were the most common (106, 65.8%), while the use of amiodarone for rhythm control and smoking within 2 years were the least common, both of 30 (18.6%). (See Table 2)

When the cut-off value of SAMe-TT$_2$R$_2$ score was set to ≥ 4, the sensitivity and specificity of predicting TTR ≥ 65% were 69.8% and 93.1%, respectively. The Youden index was 0.629. If the cut-off value of SAMe-TT$_2$R$_2$ score was set to ≤ 4, the sensitivity and specificity of predicting TTR ≥ 65% were 93.0% and 44.1%, respectively, and the Youden index was 0.371.

ROC curve (Fig. 1) evaluates the predictive power of the SAMe-TT$_2$R$_2$ score for TTR ≥ 65%. The figure showed that when the cut-off point ≥ 4, the best combination of sensitivity and specificity was shown (69.8% and 93.1%, respectively). The area under the curve AUC was 0.854.

Figure 2 shows the event-free survival curve.
Table 1
– Demographic characteristics of the sample

| Variable                                      | n = 161          |
|-----------------------------------------------|------------------|
| Female sex                                   | 106(65.8)        |
| Age (years, media (P25, P75))                 | 55.0 (47.5–59.0) |
| hypertension                                 | 38 (26.2)        |
| diabetes                                      | 44 (30.3)        |
| Coronary Heart Disease                        | 46 (31.7)        |
| Peripheral vascular disease                   | 2 (1.4)          |
| Stroke                                        | 17 (11.7)        |
| Heart failure                                 | 22 (15.2)        |
| Lung disease                                  | 13 (9.0)         |
| Liver and kidney disease                      | 7 (4.8)          |
| SAMe-TT2R2 score                              |                  |
| 2, n (%)                                      | 9 (6.3)          |
| 3, n (%)                                      | 28 (19.3)        |
| 4, n (%)                                      | 60 (41.4)        |
| 5, n (%)                                      | 40 (27.6)        |
| 6, n (%)                                      | 7 (4.8)          |
| 7, n (%)                                      | 1 (0.7)          |

Categorical variables are shown as n (%), and continuous variables, as median (25%-75%).
Table 2
– Prevalence of the SAMe-TT$^2$R$^2$ score components

| Score Component | n (%) |
|-----------------|-------|
| S | Sex (female) | 106 (65.8) |
| A | Age (< 60 years) | 76 (47.6) |
| Me | Medical history (> 2 comorbidities*) | 70 (43.5) |
| T | Treatment (amiodarone) | 30 (18.6) |
| T2 | Tobacco use (within 2 years) | 30 (18.6) |
| R2 | Race (non-Caucasian) | 161 (100) |

*: Hypertension, diabetes, coronary artery disease/myocardial infarction, peripheral artery disease, previous stroke, congestive heart failure, lung disease, liver or kidney disease

Discussion

In this study, we have shown for the first time that after mechanical mitral valve replacement, the SAME-TT$^2$R$^2$ model can effectively predict the level of TTR during the course of using oral warfarin anticoagulation, and the SAMe-TT$^2$R$^2$ score $\geq$ 4 can be used to predict TTR < 65%.

Mitral valve replacement is a common surgical treatment for heart mitral valve disease. The existing artificial valves are divided into biological valves and mechanical valves. There is a high usage rate among the young population with mechanical valve due to biological valves have a certain probability of damage.\[13\] At present, the most widely used anticoagulant after mechanical valve replacement is warfarin.\[14\] The safety window between the effective dose of warfarin and the toxic dose is very narrow. Oral warfarin treatment requires continuous monitoring of the INR.\[15\] Once there is insufficient anticoagulation strength or excessive anticoagulation strength, it will lead to bleeding and thromboembolic complications, which can be life-threatening in severe cases. The incidence of thromboembolic events after replacement ranges from 0.4–1.6% per year, and increases to 2.5% during the first postoperative month, even if the usual anticoagulation therapy is administered. Therefore, the anticoagulation quality seriously affects the quality of life of patients after mechanical valve surgery.\[16\] Time in therapeutic range (TTR) is usually used as a standard to measure the quality of anticoagulation, and TTR with more than 65% or even 70% is generally considered to be ideal for anticoagulation quality, and these patients can often benefit from it.\[17\]

It will be extremely beneficial for clinicians to create a simple and effective tool to predict whether the patients taking warfarin orally will achieve higher TTR. Based on this, Apostolakis et al proposed the SAME-TT$^2$R$^2$ model, which aimed to identify those patients with atrial fibrillation who need additional intervention during oral warfarin anticoagulation to achieve an acceptable level of warfarin control. When the score was 0–1, the target TTR could be reached, while the score $\geq$ 2 points meant TTR was poor.
Some subsequent studies have confirmed that this model can effectively predict TTR and anticoagulant adverse events. According to Chan et al. confirmed that in Chinese patients with atrial fibrillation, the SAMe-TT$_2$R$_2$ score had a good correlation with TTR. When the SAMe-TT$_2$R$_2$ score $>2$ points, TTR had high sensitivity and negative predictive value, and the risk of ischemic stroke gradually increases with the increase of the SAMe-TT$_2$R$_2$ score.\footnote{18} Fernando Pivatto Júnior et al. found that the SAMe-TT$_2$R$_2$ score can effectively predict the TTR level of oral warfarin in patients with atrial fibrillation. For patients with a higher SAMe-TT$_2$R$_2$ score ($\geq 2$ points), the anticoagulant effect of warfarin was poor while patients with low-risk (0–1 points) responded better to warfarin.\footnote{19} Rungroj et al. studied 1669 patients including 22 centers across Thailand and found that the SAMe-TT$_2$R$_2$ score was the only independent predictor of sub-optimal TTR among NVAF patients treated with warfarin.\footnote{20} However, there are some studies that shows this score cannot do so. A systematic review and simulation meta analysis conducted by Miert et al. pointed out that although the SAMe-TT$_2$R$_2$ score could predict low TTR, it’s effect was limited and not very useful clinically\footnote{21}.

Few people paid attention to the quality of anticoagulation of patients after mechanical mitral valve replacement, especially in Asia. In China, with the exception of a few large-scale cardiac treatment centers, many hospitals do not have dedicated anticoagulation clinics and anticoagulation follow-up databases.\footnote{22} How to quickly and effectively identify the patients with low TTR after mitral valve replacement is very important in busy clinical work. Our study observes for the first time that the proportion of TTR $\geq 65\%$ after mitral valve replacement only accounted for 29.5%, which indicates that the overall TTR of this group of patients is low, and it is similar to the situation in the entire Asian region.\footnote{23}\footnote{24} At the same time, we found that the SAMe-TT$_2$R$_2$ score is significantly correlated with suboptimal INR control. SAMe-TT$_2$R$_2$ score $\geq 4$ points can be used to predict those patients with TTR $< 65\%$ after mitral valve replacement. The six simple clinical variables in the SAME-TT$_2$R$_2$ model can help to determine which patients may have poor anticoagulation quality after mitral valve replacement. Clinicians can more intuitively and easily identify these patients, so as to carry out more effective intervention on them. From the event-free survival curve, the overall survival rate of patients with SAME-TT$_2$R$_2$ score $< 4$ points is better than that of patients with SAME-TT$_2$R$_2$ score $\geq 4$ points, and the sample size may be small, and there is no statistically significant difference between the two.

Our study confirms that after the mechanical mitral valve replacement, the SAME-TT$_2$R$_2$ score model can effectively predict the TTR level in the course of oral warfarin anticoagulation. The SAME-TT$_2$R$_2$ score model can help us identify those patients who may have anticoagulation complications simply and quickly, so that we can carry out early intervention, do a good job in education and strengthen monitoring, and reduce the complications caused by anticoagulation.

**Limitations**
This study is affected by the small sample size of a single center, and the future data will continue to be increased. The SAME-TT\textsubscript{2}R\textsubscript{2} model does not include all potential factors that may affect TTR, such as drinking and genetic predisposition, which may be continuously improved in future studies.

**Conclusion**

After mechanical mitral valve replacement, the SAME-TT\textsubscript{2}R\textsubscript{2} model can effectively predict the level of TTR during the course of using oral warfarin anticoagulation, and the SAMe-TT\textsubscript{2}R\textsubscript{2} score ≥ 4 can be used to predict TTR < 65%.

**Abbreviations**

TTR
time in therapeutic range
INR
international normalized ratio
SAMe-TT\textsubscript{2}R\textsubscript{2}
S, sex; A, age; Me, medical history; T,treatment; T, smoking; R, Race

**Declarations**

**Availability of data and materials**

Not applicable.

**Acknowledgements**

All authors participated in the design and analysis of the study and contributed to the manuscript development, data analysis, article writing, scheme design. Sincerely thank all patients who agreed to participate in this study. Database administrators of the Heart Transplant Center of Beijing Anzhen Hospital contributed to the data interpretation and no funding was received for this research.

**Funding**

No funding was received for this.

**Author information**

**Affiliations**

Department of Cardiology Surgery, No. 9 Ward of Cardiac-Valve Surgery & Heart Transplantation Center, Capital Medical University Affiliated Beijing Anzhen Hospital, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China
Shubin Li, Mingqiu Hu, Yuehuan Li & Xu Meng

Department of Cardiology Surgery, Dalian Municipal Central Hospital, Dalian, 116000, China

Yang Gao

Contributions

Shubin Li wrote the initial draft. All authors were involved in the concept and editing of the final version. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xu Meng.

Ethics declarations

Ethics approval and consent to participate

Written informed consent was obtained from the patient.

Consent for publication

All authors have reviewed the manuscript and given consent for publication.

Competing interests

The authors declare that they have no competing interests.

References

[1] Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–41.

[2] Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992;102(4 Suppl):445S–55S.

[3] Schmitt L, Speckman J, Ansell J Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003;15(3):213–216.

[4] Helmut Baumgartner, Volkmar Falk, Jeroen J et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal 2017; 38, 2770–2771.

[5] Uetsuka Y, Hosoda S, Kasanuki H, Aosaki M, Murasaki K, Ooki K, et al. Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single
institution using conversion from thrombotest to PT-INR. Heart Vessels 2000;15:124–8.

[6] Sun X, Hu S, Qi G, Zhou Y. Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves. Chin Med J (Engl) 2003;116:1175–8.

[7] Xu JP, Shi YK, Dong L, Wei Y, Fu B, Liu RF. Low intensity anticoagulation therapy for chinese population with heart valve replacement–3 000 cases follow-up. J Sichuan Univ (Med Sci Edi) 2016; 47: 90–2.

[8] Zhou XM, Zhuang W , Hu JG , et al. Low-Dose Anticoagulation in Chinese Patients with Mechanical Heart Valves. Asian Cardiovasc Thorac Ann 2005;13:341−4

[9] Rosendaal F, Cannegieter S, Van der Meer F, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.

[10] Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B et al Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018;154(5):1121−1201.

[11] Jones C,Pollit V,Fitzmaurice D et al. The management of atrial fibrillation: summary of updated NICE guidance. BMJ 2014;348:g3655.

[12] Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013;144:1555-1563.

[13] Sun JC, Davidson MJ, Lamy A ,et al., Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009;374,565–576.

[14] Cannegieter SC, Rosendaal FR, Briët E, Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89,635–641.

[15] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252–89.

[16] Emery RW, Emery AM, Raikar GV, et al. Anticoagulation for mechanical heart valves: a role for patient based therapy. J Thromb Thrombolysis 2008;25:18-25.

[17] Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries a s measured by time in therapeutic range. Circulation 2008; 118:2029-37.

[18] Chan PH, Hai JJ, Chan EW, et al. Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence.
[19] Fernando PJ, Rafael SS, Lucas R, et al. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. Arq Bras Cardiol 2017 Apr;108(4):290-296.

[20] Krittayaphong R, Winijkul A, Pirapatdit A, et al. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singapore Med J, 2019 Nov 4. doi: 10.11622/smedj.2019143.

[21] van Miert J, Bos S, Veeger N, et al. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PLoS One 2018;13(3):e0194208.

[22] FU B, DONG L, Shi YK. Construction of an Anticoagulation Therapy Database of Chinese Patients after Heart Valve Replacement. Chin J Clin Thorac Cardiovasc Surg 2013;20(1):3-5.

[23] Oldgren J, Healey J S, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries—the RE-LY Atrial Fibrillation Registry. Circulation 2014, 129(15):1568-1576.

[24] Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thrombosis and haemostasis 2014; 111(5):789–797.